A recent study involving ten institutions across five countries revealed that ARID1A mutations were present almost exclusively in OCCC while TP53 mutations were in non-OCCC by examining genome-wide tumor methylation and gene expression (Cunningham et al., 2022). The gene discussed is TP53; the disease is neoplasm.